Logo image of CTEK

CYNERGISTEK INC/DE (CTEK) Stock Fundamental Analysis

NYSEARCA:CTEK - NYSE Arca - US23258P1057 - Common Stock - Currency: USD

1.25  +0.02 (+1.63%)

After market: 1.25 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CTEK. CTEK was compared to 102 industry peers in the Health Care Providers & Services industry. The financial health of CTEK is average, but there are quite some concerns on its profitability. CTEK has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CTEK has reported negative net income.
CTEK Yearly Net Income VS EBIT VS OCF VS FCFCTEK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 10M -10M

1.2 Ratios

Industry RankSector Rank
ROA -55.8%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTEK Yearly ROA, ROE, ROICCTEK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 20 -20 -40 -60

1.3 Margins

Industry RankSector Rank
OM -43.25%
PM (TTM) -61.88%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTEK Yearly Profit, Operating, Gross MarginsCTEK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 50 -50

More info and screens

5

2. Health

2.1 Basic Checks

CTEK does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CTEK has been increased compared to 1 year ago.
Compared to 1 year ago, CTEK has an improved debt to assets ratio.
CTEK Yearly Shares OutstandingCTEK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M 10M
CTEK Yearly Total Debt VS Total AssetsCTEK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 10M 20M 30M 40M 50M

2.2 Solvency

CTEK has an Altman-Z score of 0.99. This is a bad value and indicates that CTEK is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for CTEK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.99
ROIC/WACCN/A
WACC8.29%
CTEK Yearly LT Debt VS Equity VS FCFCTEK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 10M 20M 30M

2.3 Liquidity

CTEK has a Current Ratio of 1.69. This is a normal value and indicates that CTEK is financially healthy and should not expect problems in meeting its short term obligations.
CTEK has a Quick Ratio of 1.69. This is a normal value and indicates that CTEK is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.69
Quick Ratio 1.69
CTEK Yearly Current Assets VS Current LiabilitesCTEK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for CTEK have decreased strongly by -52.63% in the last year.
Looking at the last year, CTEK shows a decrease in Revenue. The Revenue has decreased by -2.26% in the last year.
CTEK shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -22.99% yearly.
EPS 1Y (TTM)-52.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16037.89%
Revenue 1Y (TTM)-2.26%
Revenue growth 3Y-8.55%
Revenue growth 5Y-22.99%
Sales Q2Q%1.76%

3.2 Future

The Earnings Per Share is expected to grow by 34.71% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 17.89% on average over the next years. This is quite good.
EPS Next Y-23.1%
EPS Next 2Y-2.72%
EPS Next 3Y36.03%
EPS Next 5Y34.71%
Revenue Next Year16.51%
Revenue Next 2Y18.47%
Revenue Next 3Y17.7%
Revenue Next 5Y17.89%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CTEK Yearly Revenue VS EstimatesCTEK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
CTEK Yearly EPS VS EstimatesCTEK Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CTEK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CTEK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTEK Price Earnings VS Forward Price EarningsCTEK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.57
CTEK Per share dataCTEK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

CTEK's earnings are expected to grow with 36.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.72%
EPS Next 3Y36.03%

More info and screens

0

5. Dividend

5.1 Amount

CTEK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYNERGISTEK INC/DE

NYSEARCA:CTEK (8/31/2022, 8:04:02 PM)

After market: 1.25 0 (0%)

1.25

+0.02 (+1.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-15 2022-08-15
Earnings (Next)11-09 2022-11-09
Inst Owners5.97%
Inst Owner Change0%
Ins Owners2.94%
Ins Owner Change0%
Market Cap16.57M
Analysts43.33
Price Target1.27 (1.6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.98
P/FCF N/A
P/OCF N/A
P/B 1.09
P/tB N/A
EV/EBITDA -2.57
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.27
BVpS1.15
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -55.8%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -43.25%
PM (TTM) -61.88%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.69
Quick Ratio 1.69
Altman-Z 0.99
F-Score3
WACC8.29%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-52.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16037.89%
EPS Next Y-23.1%
EPS Next 2Y-2.72%
EPS Next 3Y36.03%
EPS Next 5Y34.71%
Revenue 1Y (TTM)-2.26%
Revenue growth 3Y-8.55%
Revenue growth 5Y-22.99%
Sales Q2Q%1.76%
Revenue Next Year16.51%
Revenue Next 2Y18.47%
Revenue Next 3Y17.7%
Revenue Next 5Y17.89%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A